Phase I/II results: First-line NALIRIFOX in patients with pancreatic ductal adenocarcinoma

Share :
Published: 8 Jul 2020
Views: 1247
Dr Zev Wainberg - Ronald Reagan UCLA Medical Center, Los Angeles, USA

Dr Zev Wainberg speaks to ecancer in an online interview for the virtual ESMO GI 2020 meeting.

He outlines the background, and study design for this phase I/II trial, which investigated first-line liposomal irinotecan irinotecan plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) in patients with pancreatic ductal adenocarcinoma.

Dr Wainberg states that a safe and tolerable dose for this regimen was established, with compelling efficacy. For this regimen, progression-free survival of 9.5 months, and a median overall survival of 12.5 months was achieved in this patient population.

He also explains the toxicity profile and the next steps for this study - which includes the launch of a the phase III NAPOLI-3 trial.